Triple negative breast cancer (TNBC) is a specific type of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). TNBC has become a hot topic of research in recent years due to its lack of endocrine and anti-HER2 therapeutic targets and its aggressive nature and poor prognosis. There is no standard treatment plan for TNBC. The consolidation treatment of TCM after chemotherapy is of great clinical significance compared with other types of breast cancer. In a study by Zhang Zhuan of Tianjin Cancer Hospital, it was found that the cellular immune function of breast cancer patients, whether actual or deficiency, was significantly decreased, which showed a significant decrease in CD+4 cells, especially in the deficiency group, with a significant increase in CD+8 cells and CD+4/CD+8 < 115, and CD+4/CD+8 < 1 in Yang Qi deficiency patients, indicating a decrease in Th cell activation and Ts cell proliferation. This indicates that the immune function of the body is suppressed, and the two types of immune regulatory cells, Th cells and Ts cells, are smoothly dysregulated. The immune function of the body includes both humoral and cellular immunity, and is composed of immune organs, immune cells and immune molecules, which is equivalent to the physiological function of Zhengqi in Chinese medicine.